Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody

Immune-oncology (IO) drug therapy is effective against various types of cancer. Although several, potential, clinical predictive markers have been identified, none so far have proven reliable. Herein we evaluated changes in serum alanine aminotransferase (ALT), which is upregulated by the accumulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Takeshi, Takeuchi, Takumi, Matayoshi, Yukihide, Namiki, Shin, Obara, Tetsuya, Imamura, Kazuhiro, Takamori, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119734/
https://www.ncbi.nlm.nih.gov/pubmed/33986326
http://dx.doi.org/10.1038/s41598-021-88744-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119734/
https://www.ncbi.nlm.nih.gov/pubmed/33986326
http://dx.doi.org/10.1038/s41598-021-88744-0

Ejemplares similares